Araim Pharmaceuticals

Araim Pharmaceuticals is a small pharmaceutical company based in Tarrytown, New York. Employing five people, the company generates an annual revenue of $2.5 million. Araim Pharmaceuticals is dedicated to developing innovative therapeutics that repair damage caused by serious diseases. The company's core innovation lies in the discovery of the Innate Repair Receptors (IRR), a global master regulator that stimulates cellular and tissue repair across various disease states. Araim Pharmaceuticals' lead compound, Cibinetide, is currently in clinical development and targets unmet medical needs in neuroscience and diabetes complications. Their research has resulted in a comprehensive peptide library of IRR activators. To date, 10 of these compounds have demonstrated in-vivo proof of concept efficacy. Araim Pharmaceuticals actively collaborates with prominent academic researchers worldwide, contributing significantly to the scientific literature in this field. For further information, please visit Araim Pharmaceuticals' website at araimpharma.com.